Michael Bartholomew, MS, brings extensive therapeutic experience across nearly twenty diseases, including medical devices and diagnostics. He previously held leadership positions at Porzio Life Sciences and Dohmen Life Science Services, as well as various roles at Pfizer, Pharmacia, and Baxter.
1 Price, John H., et al. “Accurate Prostate Biopsies Using Low-Field Portable Intervention MRI in an Ambulatory Surgical Center.” IPCU, 2024.
2 Sze, C., et al (2023). “Feasibility and preliminary clinical tolerability of low-field MRI-guided prostate biopsy.” The Prostate, 83(7), 656-662. https://doi.org/10.1002/pros.24499.
3 Sze, C., et al, (2022) “Cost-efficient analysis of a portable low field magnetic resonance imaging system for prostate cancer diagnosis.” Front.
Urol.2:966862. doi: 10.3389/fruro.2022.966862.
4 Chiragzada, S., et al. “Advantageous Detection of Significant Prostate Cancer Using a Low-Field, Office-Based MRI System.” Cureus. 2022 Dec 1;14(12):e32105. doi:10.7759/cureus.32105. PMID:
36601170; PMCID: PMC9805358.
5 Data on file.
6 Xiang, Jianjian, et al. “Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: A systematic review and meta-analysis.ˮ World Journal of Surgical Oncology, vol. 17, no. 1,13 Feb. 2019, https://doi.org/10.1186/s12957-019-1573-0.
*The Promaxo Robot is not yet available for commercial sale.
© 2024 Promaxo, Inc. All rights reserved.